Embodiments of the present invention are directed to methods for treatment of melanoma using specific inhibitors of dihydroorotate dehydrogenase (DHODH), i.e. selected form C19H14F2N2O3 C18H13F6NO4 C19H16F3NO4 C19H10F5NO4S C19H14FNO4S C20H15F4NO4 C19H17NO4 C20H17F2NO4 and C20H18FNO4, and to combination therapies that involve administering to a subject these inhibitors, together with an inhibitor of oncogenic BRAF (e.g. BRAF(V600E)).Des modes de réalisation de la présente invention concernent des procédés pour le traitement de mélanome à laide dinhibiteurs spécifiques de dihydroorotate déshydrogénase (DHODH), cest-à-dire, choisis parmi C19H14F2N2O3 C18H13F6NO4 C19H16F3NO4 C19H10F5NO4S C19H14FNO4S C20H15F4NO4 C19H17NO4 C20H17F2NO4 et C20H18FNO4, et des polythérapies qui consistent à administrer, à un sujet, ces inhibiteurs conjointement avec un inhibiteur de BRAF oncogène (par exemple, BRAF (V600E)).
